Erschienen in:
18.06.2018 | Laboratory Investigation
RUNX3 inhibits glioma survival and invasion via suppression of the β-catenin/TCF-4 signaling pathway
verfasst von:
Jikui Sun, Banban Li, Zhifan Jia, Anling Zhang, Guangxiu Wang, Zhijuan Chen, Zhende Shang, Chaocai Zhang, Jian Cui, Weidong Yang
Erschienen in:
Journal of Neuro-Oncology
|
Ausgabe 1/2018
Einloggen, um Zugang zu erhalten
Abstract
Introduction
Runt-related transcription factor 3 (RUNX3) exerts a tumor suppressor gene associated with gastric and other cancers, including glioma. However, how its anti-tumor mechanism in functions glioma is unclear.
Methods
We assayed expression of RUNX3 with a tissue microarray (TMA), frozen cancer tissues and malignant glioma cell lines using immunohistochemistry, qRT-PCR and Western bolt analysis. Cell proliferation, invasion, cell cycle distribution and apoptosis were also examined to confirm the effect of RUNX3 medicated malignant phenotype. TOP/FOP experiment was used to detect the β-catenin/Tcf-4 transcription activity by RUNX3.
Results
Enforced RUNX3 expression inhibited proliferation and invasion, induced cell cycle arrest and promoted apoptosis in vitro and in vivo, Bim siRNA partically reversed the effect of RUNX3-induced apoptosis in LN229 and U87 cells, suggesting a dependent role of Bim-caspase pathway. Moreover, Mechanism investigations revealed that restoration of RUNX3 suppressed β-catenin/Tcf-4 transcription activity.
Conclusions
RUNX3 plays a pivotal role in glioma initiation and progression as a tumor suppressor via attenuation of Wnt signaling, highlighting it as a potential therapeutic target for glioma.